The Parker Institute for Cancer Immunotherapy awards up to $2.9M to eight early-career investigators

Vanderbilt receives $1M grant to fund immunotherapy research in CRC

The Robert J. Kleberg Jr. and Helen C. Kleberg Foundation awarded a $1 million grant to support research at Vanderbilt aimed at dramatically expanding the efficacy of immunotherapy for colorectal cancer.

October 04, 2024

Vol.50 No.37

Regulatory News

ODAC votes overwhelmingly in support of PD-L1 expression as predictive biomarker for efficacy of checkpoint inhibitors
Vote applies across drugs and indications

The FDA Oncologic Drugs Advisory Committee on Sept. 26 voted that PD-L1 inhibitors should not be indicated for patients with PD-L1-negative gastric/gastroesophageal junction adenocarcinoma and esophageal squamous cell carcinoma.

Immunotherapy before and after lung cancer surgery reduces death risk, disease recurrence

People with operable non-small cell lung cancers may fare better over the next few years by receiving immunotherapy treatments before and after surgery instead of only before surgery, according to an analysis by Johns Hopkins Kimmel Cancer Center investigators.

September 13, 2024

Vol.50 No.34

Drugs & Targets

FDA approves Tecentriq Hybreza for subcutaneous PD-(L)1 cancer immunotherapy

FDA approved Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs), the first and only PD-(L)1 inhibitor for subcutaneous injection.

September 13, 2024

Vol.50 No.34

Clinical Roundup

UTSW study reveals widespread disparities in immunotherapy use for patients with advanced kidney and bladder cancers

A study led by researchers at UT Southwestern Medical Center reveals significant disparities across the country in the use of immunotherapy for patients with advanced kidney and bladder cancers.

September 06, 2024

Vol.50 No.33

Clinical Roundup

Sarclisa combination improves PFS in newly diagnosed MM in phase III trial

Data from the IMROZ phase III trial demonstrated Sarclisa (isatuximab), in combination with standard-of-care bortezomib, lenalidomide, and dexamethasone (VRd) followed by Sarclisa-Rd (the IMROZ regimen), significantly reduced the risk of disease progression or death by 40%, compared to VRd followed by Rd in patients with newly-diagnosed multiple myeloma not eligible for transplant.

August 09, 2024

Vol.50 No.32

The Parker Institute for Cancer Immunotherapy awards up to $2.9M to eight early-career investigators

YOU MAY BE INTERESTED IN

Vanderbilt receives $1M grant to fund immunotherapy research in CRC

ODAC votes overwhelmingly in support of PD-L1 expression as predictive biomarker for efficacy of checkpoint inhibitors
Vote applies across drugs and indications

Immunotherapy before and after lung cancer surgery reduces death risk, disease recurrence

FDA approves Tecentriq Hybreza for subcutaneous PD-(L)1 cancer immunotherapy

UTSW study reveals widespread disparities in immunotherapy use for patients with advanced kidney and bladder cancers

Sarclisa combination improves PFS in newly diagnosed MM in phase III trial

Renew today!

Subscriber content

Login

The Parker Institute for Cancer Immunotherapy awards up to $2.9M to eight early-career investigators

YOU MAY BE INTERESTED IN

Vanderbilt receives $1M grant to fund immunotherapy research in CRC

ODAC votes overwhelmingly in support of PD-L1 expression as predictive biomarker for efficacy of checkpoint inhibitorsVote applies across drugs and indications

Immunotherapy before and after lung cancer surgery reduces death risk, disease recurrence

FDA approves Tecentriq Hybreza for subcutaneous PD-(L)1 cancer immunotherapy

UTSW study reveals widespread disparities in immunotherapy use for patients with advanced kidney and bladder cancers

Sarclisa combination improves PFS in newly diagnosed MM in phase III trial

Login

ODAC votes overwhelmingly in support of PD-L1 expression as predictive biomarker for efficacy of checkpoint inhibitors
Vote applies across drugs and indications